MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12886-024-03779-x

Медицинская библиотека · BMC ophthalmology · 2024

Tocilizumab for the management of corticosteroid-resistant GO combined with OMG: a case series.

Guo Chenjun, Wang Ping, Zhang Shaobo, Cheng Qilin, Zhang Qiong, Ma Nan, Li Yangjun

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: To highlight the safety and efficacy of tocilizumab (TCZ) in Graves' ophthalmopathy (GO) combined with ocular myasthenia gravis (OMG) patients refractory to steroids and cholinesterase inhibitor (CEI).

METHODS

This was retrospective case series. We reviewed the health records of patients with GO combined with OMG, ten of whom were refractory to corticosteroids and CEI treatment and received intravenous injection of TCZ. Ten patients were treated with four injections of TCZ (intravenously, 8 mg per kilogram of body weight, once a month). We analyzed the efficacy and safety of TCZ treatment for this subset of patients with GO and OMG.

RESULTS

The main outcomes including quality of life questionnaire in Graves' orbitopathy (GO-QoL) score, Clinical Activity Score (CAS), Myasthenia Gravis Activities of Daily Living profile (MG-ADL) score, proptosis, diplopia and ptosis were assessed at 3 time points: "Baseline" (before the TCZ injection), "4th month" (after fourth time TCZ injection), "Follow up" (Last follow-up). Comparing parameters at 4th month vs. at baseline, all indicators improved at 4th month including GO-QoL score of visual functioning subscale (82.29 ± 13.71 vs. 35.98 ± 20.66, P < 0.001), GO-QoL score of the appearance subscale (80 ± 8.75 vs. 40.63 ± 17.95, P < 0.001), CAS (1.3 ± 0.46 vs. 4.5 ± 0.81, P < 0.001), MG-ADL (2.5 ± 1.56 vs. 5.11 ± 1.14, P < 0.001). Furthermore, proptosis decreased from 19.73 ± 2.84 to 17.93 ± 2.26 mm at 4th month (P < 0.0001). Diplopia and ptosis were also resolved at 4th month. After following up for a minimum of 11 months, the patients had no signs of relapse. In addition, we observed that all analyzed patients exhibited no significant drug reactions following the administration of TCZ.

CONCLUSION

Tocilizumab maybe a useful therapeutic option in refractory GO coexisting with OMG. However, considering the limitation of a retrospective study, short follow up period and small sample size of this study, randomized controlled studies are needed to validate our results.

Для цитирования: Guo Chenjun, Wang Ping, Zhang Shaobo, Cheng Qilin, Zhang Qiong, Ma Nan, Li Yangjun. Tocilizumab for the management of corticosteroid-resistant GO combined with OMG: a case series.. BMC ophthalmology. 2024. DOI: 10.1186/s12886-024-03779-x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.